3 results
Primary:To provide access to abrocitinib to adolescent and adult patients with or without background topical therapy who have inadequate treatment options due to inadequate response or intolerance to available approved medicated topical and systemic…
Primary Objective• To estimate the long term safety of 100 mg and 200 mg once daily (QD) of abrocitinib with or without topical treatments in adult and adolescent subjects who previously participated in qualifying abrocitinib atopic dermatitis (AD)…
Primary objective: To evaluate the comparative long-term safety of TAK-503 treatment (formerly known as SPD503) in children and adolescentsaged 6 to 17 years diagnosed with ADHD for whom stimulants are not suitable, not tolerated, or shown to…